Rite Aid (RAD) Stock Continues Climb After Same-Store Sales Report

NEW YORK (TheStreet) -- Rite Aid  (RAD) stock continued to rise Monday after the drugstore chain reported an increase in June same-store sales last week.

The company announced a 3.9% increase in June with a 5.4% rise in same-store sales in its pharmacy section. The increase included a -1.69% effect from new generic-drug introductions. The company also noted prescription sales made up 68.4% of drugstore sales.

Rite Aid also said total drugstore sales rose 3.5% to $2 billion in June. Same-store sales climbed 0.9% in the front end of the store last month.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 2.05% to $7.72 at 10:02 a.m.

Separately, TheStreet Ratings team rates RITE AID CORP as a "hold" with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate RITE AID CORP (RAD) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and poor profit margins."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

If you liked this article you might like

Walgreens Is Primed to Rally, With or Without Rite Aid

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

Walgreens to Tweak Number of Rite Aid Stores It Buys to Win Regulatory Approval

Will the FTC Let Walgreens Go on a $5.2 Billion Rite Aid Shopping Spree?